Biodesix Validates Thermo Fisher's Oncomine Dx Express Test for Solid Tumors on Genexus Dx Integrated Sequencer.
ByAinvest
Tuesday, Aug 19, 2025 9:49 am ET1min read
BDSX--
The company recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer. This achievement underscores Biodesix's role in the development and validation of diagnostic tools crucial for cancer research and treatment [2].
Biodesix Development Services will contribute to the development of diagnostic tests and tools, aiming to improve cancer diagnosis and care. The company's collaboration with Thermo Fisher is part of a broader initiative to advance NGS-based diagnostics and precision medicine [1].
Scott Hutton, CEO at Biodesix, expressed his excitement about the designation, stating, "Being a member of Thermo Fisher’s COE network puts us in excellent company with other global groups committed to transforming cancer diagnosis and care. We are excited about the potential to offer the Oncomine Dx Express Test in the future" [1].
Upcoming presentations will provide more information on the Thermo Fisher NGS precision oncology solution and Biodesix's application of this technology for industry clients and healthcare professionals [1].
References:
[1] https://www.stocktitan.net/news/BDSX/biodesix-recognized-as-a-thermo-fisher-scientific-center-of-l4w8ty9i7iz1.html
[2] https://www.globenewswire.com/news-release/2025/08/19/3135801/0/en/Biodesix-Recognized-as-a-Thermo-Fisher-Scientific-Center-of-Excellence-COE-for-NGS-Diagnostics.html
TMO--
Biodesix has been recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS diagnostics. The company recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer. This designation reflects Biodesix's expertise in molecular diagnostics and NGS testing capabilities. Biodesix Development Services will contribute to the development of diagnostic tests and tools, aiming to improve cancer diagnosis and care.
Biodesix, Inc. (Nasdaq: BDSX), a leader in personalized diagnostics, has been recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS diagnostics. This designation reflects Biodesix's expertise in molecular diagnostics and NGS testing capabilities [1].The company recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer. This achievement underscores Biodesix's role in the development and validation of diagnostic tools crucial for cancer research and treatment [2].
Biodesix Development Services will contribute to the development of diagnostic tests and tools, aiming to improve cancer diagnosis and care. The company's collaboration with Thermo Fisher is part of a broader initiative to advance NGS-based diagnostics and precision medicine [1].
Scott Hutton, CEO at Biodesix, expressed his excitement about the designation, stating, "Being a member of Thermo Fisher’s COE network puts us in excellent company with other global groups committed to transforming cancer diagnosis and care. We are excited about the potential to offer the Oncomine Dx Express Test in the future" [1].
Upcoming presentations will provide more information on the Thermo Fisher NGS precision oncology solution and Biodesix's application of this technology for industry clients and healthcare professionals [1].
References:
[1] https://www.stocktitan.net/news/BDSX/biodesix-recognized-as-a-thermo-fisher-scientific-center-of-l4w8ty9i7iz1.html
[2] https://www.globenewswire.com/news-release/2025/08/19/3135801/0/en/Biodesix-Recognized-as-a-Thermo-Fisher-Scientific-Center-of-Excellence-COE-for-NGS-Diagnostics.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet